Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
Recruiting · NCT07222280 · Interventional (participants receive a specific treatment) · Lead sponsor: Covenant Health, US
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
Who can take part
Inclusion criteria
- Ages 60 to 90 years old
- No prior diagnosis of dementia
- Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state
Exclusion criteria
- Age under 60 years
- Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
Where it is running
6 locations listed across 1 US state.
- Cumberland Medical Center - Crossville, Tennessee, United States
- Roane Medical Center - Harriman, Tennessee, United States
- Fort Sanders Regional Medical Center - Knoxville, Tennessee, United States
- Fort Loudon Medical Center - Lenoir City, Tennessee, United States
- Methodist Medical Center - Oak Ridge, Tennessee, United States
- LeConte Medical Center - Sevierville, Tennessee, United States